Ramírez-Marín R, Razo-Blanco-Hernández DM, Lima-Gómez V

Language: Spanish
References: 20
Page: 191-195
PDF size: 169.85 Kb.

ABSTRACT

Introduction: Macular degeneration related to age causes 7% of blindness and 3% of visual deficiency in the world. The prevalence is 8.6% between 45 and 85 years; it is one of the causes of irreversible blindness in people over 50 years. The treatment is based on the stage of the illness. Visual acuity is the most easily identifiable indicator of advanced disease. Objective: To determine the best-corrected visual acuity at the time of diagnosis of the disease. Material and methods: An observational, descriptive, retrospective, transversal, open study. Subjects diagnosed with any form of the disease, any gender and age, treated at the Hospital Juárez de México from January 2013 to June 2017 were included. Best corrected visual acuity was documented in each form of the disease by mean and standard deviation; we also calculated the 95% confidence intervals. Results: We assessed 114 cases, with 219 affected eyes; 73.97% corresponding to the non-neovascular form and 26% to the neovascular form. The mean age was 79.7 years. Best corrected visual acuity was 0.61 in the LogMAR scale (20/80 Snellen equivalent), considering both forms of the disease; patients with neovascular disease presented visual acuity of 1.03 in the LogMAR scale (20/200, Snellen equivalent). No higher frequency of diabetes mellitus or arterial hypertension was found in the patients studied. Conclusion: The mean best-corrected visual acuity was 0.6165 in the LogMAR scale. Twenty percent of the sample had a visual acuity considered legal blindness at the moment of the diagnosis.

REFERENCES

1. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995; 39(5): 367-74.

2. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2(2): e106-16.

3. Choudhury F, Varma R, Klein R, Gauderman WJ, Azen SP, McKean-Cowdin R, et al. Age-related macular degeneration and quality of life in Latinos. The Los Angeles Latino Eye Study. JAMA Ophthalmology 2016; 134(6): 683-90.

4. Tan JS, Mitchell P, Kifley A, Flood V, Smith W, Wang JJ. Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol 2007; 125(8): 1089-95.

5. Myers CE, Klein BE, Gangnon R, Sivakumaran TA, Iyengar SK, Klein R. Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2014; 121(10): 1949-55.

6. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010; 10: 31.

7. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308(5720): 419-21.

8. Bressler SB, Muñoz B, Solomon SD, West SK; Salisbury Eye Evaluation (SEE) Study Team. Racial differences in the prevalence of age related macular degeneration. The Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol 2008; 126(2): 241-5.

9. Vanderbeek BL, Zacks DN, Talwar N, Nan B, Musch DC, Stein JD. Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network. Am J Ophthalmol 2011; 152(2): 273-82.e3.

10. Spraul CW, Grossniklaus HE. Characteristics of Drusen and Bruch’s membrane in postmortem eyes with age-related macular degeneration. Arch Ophthalmol 1997; 115(2): 267-3.

11. Abdelsalam A, Zarbin MA. Review of Drusen pathogenesis, natural history and laser photocoaguation-induced regression in age-related macular degeneration. Surv Ophthalmol 1999; 44(1): 1-29.

12. Van der Schaft TL, Mooy CM, de Bruijn WC, Oron FG, Mulder PG, de Jong PT. Histologic features of the early stages of age-related macular degeneration: a statistical analysis. Ophthalmology 1992; 99: 278-86.

13. Sardell RJ, Persad PJ, Pan SS, Whitehead P, Adams LD, Laux RA, et al. Progression rate from intermediate to advanced age- related macular degeneration is correlated with the number of risk alleles at the CFH locus. Invest Ophthalmol Vis Sci 2016; 57(14): 6107-15.

14. Sana N, Nadia K. Clinical diagnosis, classification, and patient counseling, In: Duker JS, Witkin AJ. Age-Related Macular Degeneration: Current Management. Ch. 3. Boston, Massachusetts: Ed. SLACK; 2015. p. 31-34.

15. Sunness JS, Rubin GS, Applegate CA, Bressler NM, Marsh MJ, Hawkins BS, et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy od the macular and good visual acuity. Ophthalmology 1997; 104: 1677-91.

16. AREDS2 Research Group, Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, et al. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 Report Number 1). Ophthalmology 2012; 119(11): 2282-9.

17. Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120(1): 122-9.

18. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012; 119(3): 571-80.

19. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública (MX); 2012.

20. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104(1): 7-21.